CN101242809A - 方法 - Google Patents

方法 Download PDF

Info

Publication number
CN101242809A
CN101242809A CNA2006800295637A CN200680029563A CN101242809A CN 101242809 A CN101242809 A CN 101242809A CN A2006800295637 A CNA2006800295637 A CN A2006800295637A CN 200680029563 A CN200680029563 A CN 200680029563A CN 101242809 A CN101242809 A CN 101242809A
Authority
CN
China
Prior art keywords
inhibitor
water
arbitrary
particles
insoluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800295637A
Other languages
English (en)
Chinese (zh)
Inventor
L·林德福斯
U·斯坎特泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101242809A publication Critical patent/CN101242809A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CNA2006800295637A 2005-08-12 2006-08-09 方法 Pending CN101242809A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501807 2005-08-12
SE05018072 2005-08-12

Publications (1)

Publication Number Publication Date
CN101242809A true CN101242809A (zh) 2008-08-13

Family

ID=37757817

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800295637A Pending CN101242809A (zh) 2005-08-12 2006-08-09 方法

Country Status (13)

Country Link
US (1) US20080193534A1 (https=)
EP (1) EP1915131A4 (https=)
JP (1) JP2009505976A (https=)
KR (1) KR20080033383A (https=)
CN (1) CN101242809A (https=)
AU (1) AU2006280511A1 (https=)
BR (1) BRPI0614904A2 (https=)
CA (1) CA2618468A1 (https=)
IL (1) IL188971A0 (https=)
MX (1) MX2008001919A (https=)
NO (1) NO20081311L (https=)
WO (1) WO2007021228A1 (https=)
ZA (1) ZA200800919B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113507834A (zh) * 2019-03-27 2021-10-15 先正达农作物保护股份公司 具有减少的晶体生长的杀真菌剂配制品

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097165A1 (en) * 2007-02-09 2008-08-14 Astrazeneca Ab Process for preparation of a stable dispersion of solid amorphous submicron particles in an aqueous medium
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
US8920682B2 (en) * 2010-03-19 2014-12-30 Eastern Michigan University Nanoparticle dispersions with ionic liquid-based stabilizers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5110717A (en) * 1990-12-17 1992-05-05 Eastman Kodak Company Stability improvement of amorphous particle dispersions
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
GB9319129D0 (en) * 1993-09-15 1993-11-03 Dowelanco Ltd Storage and dilution of stable aqueous dispersions
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
CA2407027C (en) * 2000-04-20 2011-02-15 Rtp Pharma Inc. Improved water-insoluble drug particle process
CN1254233C (zh) * 2001-08-06 2006-05-03 阿斯特拉曾尼卡有限公司 含有水不溶性的稳定纳米颗粒和赋形剂如中链甘油三酯(mct)的水性分散体
CA2470533A1 (en) * 2002-01-14 2003-07-24 Dow Global Technologies Inc. Drug nanoparticles from template emulsions
ATE395044T1 (de) * 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
US6825209B2 (en) * 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
PL372202A1 (en) * 2002-06-11 2005-07-11 Merck Patent Gmbh Modified byrodin 1 with reduced immunogenicity
US7390505B2 (en) * 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113507834A (zh) * 2019-03-27 2021-10-15 先正达农作物保护股份公司 具有减少的晶体生长的杀真菌剂配制品
US12414564B2 (en) 2019-03-27 2025-09-16 Syngenta Crop Protection Ag Fungicide formulations with reduced crystal growth

Also Published As

Publication number Publication date
KR20080033383A (ko) 2008-04-16
ZA200800919B (en) 2008-12-31
WO2007021228A1 (en) 2007-02-22
EP1915131A4 (en) 2012-07-25
US20080193534A1 (en) 2008-08-14
IL188971A0 (en) 2008-08-07
CA2618468A1 (en) 2007-02-22
NO20081311L (no) 2008-05-13
AU2006280511A1 (en) 2007-02-22
MX2008001919A (es) 2008-03-24
BRPI0614904A2 (pt) 2012-12-25
EP1915131A1 (en) 2008-04-30
JP2009505976A (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
JP4714412B2 (ja) 水不溶性の活性でかつ賦形剤様の中鎖トリグリセリド（ｍｃｔ）の安定なナノ粒子を含む水性分散液
Jatwani et al. An overview on solubility enhancement techniques for poorly soluble drugs and solid dispersion as an eminent strategic approach
AU2002317409A1 (en) Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (MCT)
Yadav et al. Nanosuspension: A promising drug delivery system
Chavhan et al. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects
US20190091165A1 (en) Method for preparing nanoparticle of active ingredient using lipid as lubricant in milling process
CN101242809A (zh) 方法
Thenge et al. Nanocrystals in the drug delivery system
CN101605533B (zh) 制备固体非晶亚微米颗粒在水性介质中的稳定分散体的方法
Ganesh et al. Nanosuspension: A novel drug delivery system
Wanole REVIEW ON: NANOSUSPENSION
ES2292300B1 (es) Procedimiento para la obtencion de un material compuesto.
Mirzapure Enhancing Medication Solubility Using Nanosuspension: A Method
ZA200400847B (en) Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like Middle Chain Triglycerides (MCT).
VERMA et al. Indian Journal of Novel Drug Delivery An Official Publication of
Ginoya et al. NANOSUSPENSION: A NOVEL APPROACH TOWARDS THE DRUG DELIVERY SYSTEM.
Sunil et al. Perspectives in Nanosuspension drug delivery.
HK1064048B (en) Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080813